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Aperistaltic effect of hyoscine N-butylbromide
versus glucagon on the small bowel assessed
by magnetic resonance imaging
Abstract The aim of this prospective
study was to compare the intraindi-
vidual aperistaltic effect of 40 mg
hyoscine N-butylbromide (HBB/
Buscopan) with that of 1 mg gluca-
gon on small bowel motility by using
magnetic resonance imaging (MRI).
Ten healthy volunteers underwent
two separate 1.5-T MRI studies
(HBB/glucagon) after a standardized
oral preparation with an aqueous
solution of Gd-DOTA and ispaghula
(Metamucil). A 2D T1-w GRE se-
quence was acquired (TR 2.7 ms/TE
1.3 ms, temporal resolution 0.25 s)
before and after intravenous (i.v.)
drug administration and motility was
followed over 1 h. On the resulting
images the cross-sectional luminal
diameters were assessed and plotted
over time. Baseline motility frequen-
cy, onset of aperistalsis, duration of
arrest, reappearance of motility and
return to normal motility were
analysed. Significant differences re-
garding reliability and duration of
aperistalsis were observed. In the
HBB group aperistalsis lasted a mean
of 6.8±5.3 min compared with 18.3±
7 min after glucagon (p<0.0001). In
50% of cases HBB did not accom-
plish aperistalsis, whereas glucagon
always succeeded (p=0.05). There
were no significant differences in
terms of baseline and end frequencies
for the onset of aperistalsis (22.2±
37.5 s HBB/13.4±9.2 s glucagon,
p=0.1), nor for the return to normal
motility. Arrest of small bowel mo-
tion is achieved more reliably and
lasts significantly longer after i.v.
administration of 1 mg glucagon
compared with 40 mg HBB.
Keywords Small intestine . Magnetic
resonance imaging . Gastrointestinal
motility . Hyoscine N-butylbromide .
Glucagon . Antispasmodic drugs
Introduction
Small bowel peristalsis causes movement artefacts in MRI
and computed tomography (CT) examinations that can
impede the diagnostic quality of abdominal and pelvic
studies [1–3]. A spasmolytic agent is therefore commonly
administered intravenously to inhibit bowel motion shortly
before performing abdominal imaging studies. The two
main paralysing agents used in clinical routine are hyoscine
N-butylbromide (HBB; Buscopan®, Boehringer Ingel-
heim, Germany) and glucagon (GlucaGen®, Novo Nor-
disk, Küsnacht, Switzerland). HBB is a well-known
anticholinergic compound with a high tissue affinity for
muscarinic receptors located on visceral smooth muscles of
the gastrointestinal tract where it has a relaxing/spasmo-
lytic effect [4].
Glucagon is a protein comprising 29 amino acids which
is produced by expression of recombinant DNA in a
Saccharomyces cerevisiae vector. Glucagon exerts para-
lytic effects on the gastrointestinal smooth muscle by
acting on the stimulatory G-protein-coupled glucagon
receptors, which are distributed throughout the gastroin-
testinal tract [5]. Although the pharmacological properties
of hyoscine N-butylbromide and glucagon are completely
different their effect on bowel peristalsis is the same, both
leading to aperistalsis. Little has been reported on their
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effect on small bowel motility, particularly for inhibiting
bowel wall motion in cross-sectional imaging [6–8].
There is an ongoing discussion on the relative merits of
these two agents, mainly focused on the onset time,
duration and location of their effects [8].
MR motility imaging of the small bowel was introduced
in recent years allowing visualisation, quantification and
characterisation of small bowel motility [6]. The MRI
method proposed here is based on ultrafast imaging by
repeated acquisition on the same image plane covering
large portions of the small bowel and allowing direct
visualisation of small bowel wall movement. The aim of
this prospective volunteer study was to characterise and
compare the paralytic effect of HBB versus that of
glucagon on small bowel motility based on MRI measure-
ments over a period of 60 min.
Materials and methods
Study population
The MRI studies were performed between December 2004
and January 2006. The study population (five female; five
male) comprised healthy nonsmokers, with an average age of
32 years, a BMI of 22 kg/m2 (19–29 kg/m2), with no known
small bowel diseases or contraindications toMRI. Each of the
volunteers agreed to undergo two identical MRI procedures,
once with 40 mg HBB and once with 1mg glucagon. There
was an interval of at least 2 weeks and no more than 2 months
between the two imaging sessions. The study was approved
by the hospital’s ethics committee and informed written
consent was obtained from all ten volunteers.
Preparation
Each volunteer received an oral administration of a
standardised combination of 20 ml Gd-DOTA (gadoterate,
Dotarem®, Guerbet, Aulnay sur Bois, France) and 0.2 g/kg
body weight of ispaghula fibres (Metamucil®, Proctor and
Gamble, Ohio, USA), dissolved in 1,200 ml tap water. This
solution was ingested continuously by the volunteers over
a period of 2 h before imaging, providing a standardised
distension of the entire small bowel.
Imaging and drug administration
The study was performed on a 1.5-T MRI unit (Intera
Achieva, Philips Medical System, Best, the Netherlands)
using a 4-channel SENSE body surface coil (phased array
coil). Imaging was performed in apnoea with the volunteer
prone. To aid in choosing the optimal coronal slice for
measuring motility, an initial coronal 3D-balanced fast-
field-echo (bFFE) pulse sequence covering the whole
abdomen was applied for 30 s in apnoea with the following
parameters: TR 4.4 ms, TE 1.3 ms, flip angle 20°, FOV
420 mm, rectangular FOV 95%, matrix 512×512, SENSE
factor 2, 80 slices, slice thickness 1.5 mm, partial echo. The
quality of this initial pulse sequence was hampered by the
active bowel motion. To monitor motility, a 2D T1-
weighted gradient-echo sequence was used with the
following parameters: TR 2.7 ms, TE 1.3 ms, flip angle
45°, FOV 500 mm, rectangular FOV 95%, slice thickness
10 mm, matrix 192×512, SENSE factor 2 with a single
slice assessment time of 0.25 s. The preferred direction of
image acquisition alternated between the coronal and
sagittal planes with interleaved acquisition order. This
sequence can be repeated as long as required, in our
protocol for a period of 1 h. A total of 40 consecutive
sequences were therefore acquired within one study
examination; the complete setup for the imaging study is
summarised in Fig. 1.
Once the “baseline sequence” to analyse normal motility
had been obtained in a 20-s apnoea phase, a bolus of either
40 mg HBB or 1 mg glucagon was injected intravenously
into the antecubital arm vein and flushed by a bolus of
20 ml saline (0.9% NaCl). Volunteers were not aware
which drug was being injected. After administration of the
drug, the first 2D sequence of the study series was applied
with scanning for 40 s, again in apnoea, followed by a 20-s
break for breathing. After that, a sequence was repeated
every minute for the next 20 min, each time with MR data
acquired for 20 s followed by a 40-s pause for breathing.
After 20 min the recording interval was prolonged to 2 min
consisting of 20-s image acquisition followed by a 1 min
40 s interval for breathing. After drug injection, the overall
follow-up time was 1 h. All volunteers were monitored for
adverse effects or late reaction for approximately 90 min
after drug administration.
Image analysis
All recorded studies were reviewed blinded for the given
drug. Evaluation began by choosing single well-distended
segments at five different locations within the abdomen.
Measurement was done orthogonally to the long axis of
the small bowel resulting in cross-sectional diameters of
the small bowel over time (Fig. 2). On the sagittal plane the
chosen measurement site was at the level of the duodenum,
directly beneath the stomach. On the coronal plane cross-
sectional diameters were measured at five different levels
of the small bowel; at the level of the proximal and distal
jejunum, and at the proximal, mid- and preterminal ileum
(Fig. 3). Measurement locations were defined on the first
slice, then propagated through the complete stack and
adjusted for diameter on each slice in order to exactly
depict the lumen diameter. Because of breathing, the
measured location slightly shifted and had to be manually
adjusted.
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The measurements were plotted over time separately
for each volunteer, each drug and for each location by
one blinded reader. The resulting 240 plots (from 6
locations within 10 volunteers receiving two different
drugs, pre- and postadministration of the drug) were
evaluated in consensus by two other blinded readers.
On each of the 120 plots acquired before injection of
the spasmolytic agent, baseline motility frequency was
assessed where frequency was defined as the number
of “valleys” on the plot (a valley defined as a
contraction of the small bowel leading to a decrease
in its diameter, a “hill” as the maximum distension of
the same small bowel segment) correlated to the
measurement time of 20 s and extrapolated up to
1 min (Fig. 4). On each of the 120 plots after injection
the following time points were assessed: onset of
paralysis, reappearance of small bowel motility and
finally the delay until motility normalised. Examples of
all these time points are shown in Fig. 5. The time
point of paralysis was defined as the flattening of the
plot down to an amplitude smaller than 20% of the
baseline amplitude. Reappearance represented the time
Fig. 2 Image of a single bowel segment magnified from a dynamic
MRI of the small bowel. The bowel loop is shown at different time
points within the same dynamic sequence. At one time it is
distended (a), at another contracted (b), and at yet another relaxed
again (c). Measurement of the cross-sectional diameters along this
segment allows assessment of small bowel motility
Fig. 3 Coronal slice of a 2D T1-w GRE sequence for the detection
of small bowel motility after administration of 1,200 ml water
spiked with 0.2 g/kg BW ispaghula and 20 ml Gd-DOTA. On each
of the slices the diameter of the small bowel was measured at five
different locations: the proximal and the distal jejunum, and the
proximal, mid- and preterminal ileum. The diameters were measured
orthogonally to the long axis of the bowel segment
Fig. 1 Sequence algorithm for the evaluation of small bowel
motility. The first sequence lasted 40 s with a break of 20 s to breath,
whereas all succeeding ones were acquired over a period of 20 s.
Initially, the pauses in between the sequences were 40 s for the first
20 min followed by 1 min and 40 s up to the end of the experiment
with 60 min after the injection of the study drug
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point where the amplitude again exceeded the prior
limit of 20% but without a regular pattern of the curve.
Normalisation was defined as the return to an ampli-
tude similar to the baseline (±10%), with a regular
sinusoidal curve form and a constant frequency over a
minimum of three subsequent measurements. The
difference between initiation of paralysis and reappear-
ance of first motility constitutes the actual time of drug
effect needed for imaging. Normalised motility was
defined as return of the motility curve to a sinusoidal
pattern resembling the baseline patterns, as described
previously [6].
Statistical analysis
Mean values of all measured parameters such as onset of
paralysis, duration of paralysis, reappearance of first
bowel motion and time to nomalisation were compared
statistically within the two groups based on the location
(i.e. reapperance of first bowel motion in the HBB group
on the level of the duodenum versus on the level of
proximal ileum). The location-dependent mean values
were compared between the two drug groups (i.e. time of
onset on the level of duodenum in the HBB group versus
in the glucagon group). Finally all time-dependent
parameters were compared between both treatment groups
by averaging all data for all locations (i.e. time to
normalization of all volunteers over all locations in the
HBB group versus all volunteers over all locations in
the glucagon group). Statistical analysis was done using
the two-sided paired Student’s t test on the hypothesis that
there was no difference in the measured parameters. A
value of p<0.05 was considered to be statistically
significant.
Results
All ten volunteers showed a high degree of compliance
during the two MRI examinations (one for each drug). No
one dropped out and all imaging sequences could be
evaluated for all volunteers.
Only minor adverse effects were noted for each drug
shortly after administration. Three volunteers had a short
period of dizziness, two in the HBB group and one in the
glucagon group. No serious adverse effects or late reactions
were registered during the 90-min post-drug-administration
monitoring period.
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Fig. 4 Plot of baseline motility before the administration of an
antiperistaltic drug (20 s). This plot represents the small bowel
cross-sectional diameter measurements over time of a single
volunteer on the level of the preterminal ileum. Measurement of
contraction frequency was based on the number of valleys (arrows)
indicating a narrowing of the small bowel segment diameter. The
number of valleys was extrapolated up to 1 min to get an estimate of
contractions per minute. The average contraction rate was 8.5 per
min for all volunteers before and after drug administration and
independent of the applied drug
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The plots for each volunteer, regarding the different
locations and for the two study drugs, were individually
analysed. The results below correspond to the mean values
(± standard deviation) of these assessed parameters.
The baseline frequency of the small bowel contraction
showed 8.5±1.75 contractions per min before spasmolytic
drug administration. The two groups did not differ with
regard to baseline frequency (p=0.91). This shows that
each volunteer had an equal baseline frequency before the
two postadministration MRI examinations. The baseline of
the study and the preparation scheme are therefore both
inter- and intraindividually comparable, underlining the
method’s good reproducibility.
The mean interval between injection and paralysis of
small bowel motility was 22.2±37.5 s for HBB versus
13.4±9.2 s for glucagon, both being relatively rapid. The
difference for the onset time of paralysis was not
statistically significant (p=0.1). Moreover, no significant
difference was noted between the various locations within a
single group or intraindividually between the two groups.
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Fig. 5 Plots of the contractions of small bowel segments monitored
over a period of 1 h after i.v. injection of 1 mg glucagon (a) or
40 mg HBB (b). Each plot depicts the small bowel cross-sectional
diameter changes over time for one volunteer on the level of the
terminal ileum. On these plots the following time points were
evaluated: 1 onset of paralysis, 2 first motion after paralysis, 3 return
to normal motility. The timespan between 1 and 2 is the important
phase for cross-sectional imaging free of bowel-induced motion
artefacts. These time points were analysed for each volunteer on six
different levels, separately for each drug (corresponding to a total of
240 evaluated plots). Glucagon has a significantly longer paralysis
effect than HBB
Table 1 Small bowel peristaltic movement frequencies per min, duration of complete arrest, normalisation
Parameters HBB (Buscopan®) Glucagon P value
Baseline frequency (contractions per min) 8.5±2 8.5±1.5 0.91
Onset of effect (s) 22.2±37.5 13.4±9.2 0.1
First movement (min) 6.8±5.3 18.3±7 <0.0001
Most frequent location of first movement Jejunum Terminal ileum
Delay to normalisation (min) 23±14.9 33±6.1 0.08
Terminal frequency (contractions per min) 9.5±1.7 9.7±1.8 0.45
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In the HBB group only five volunteers achieved complete
arrest of bowel motion, whereas all volunteers in the
glucagon group attained complete paralysis. The difference
for achieving paralysis between the two drugs was
statistically significant (p=0.05).
A significant difference was found regarding the
duration of effect for the two drugs. In the HBB group,
the first reappearance of small bowel motility was observed
after a mean period of 6.8±5.3 min, whereas in the
glucagon group this did not occur until after 18.3±7 min
(p<0.0001). However, the duration of this pharmacological
effect showed significant intraindividual differences for
both drugs resulting in a large standard deviation (range
39 s up to 50 min). Finally, no significant difference (p=
0.08) was measured between the two drugs for the return to
normal motility, even though a slight tendency for a more
delayed normalisation was noted for glucagon (23±
14.9 min for HBB versus 33±6.1 min for glucagon). The
motility of all volunteers returned to normal before each
of the two studies were completed. The end frequencies
for both groups at the end of the two examinations were
9.7±1.8 contractions per minute after administration of
glucagon and 9.5±1.7 after administration of HBB,
which is not statistically significant (p=0.45). There
was also no significant difference between the groups
regarding pre- and postspasmolysis frequencies (p=0.2).
Table 1 summarises the various parameters measured pre-
and post-drug administration.
Discussion
Reduction of bowel motion is essential to improving the
quality of abdominal or pelvic MRI. Without spasmolytic
drugs, however, multiple pulse sequences with longer
acquisition times are susceptible to bowel motion, produ-
cing only blurred and clinically undesirable images, thus
hampering diagnostic quality [7–9]. There is an ongoing
discussion on the relative merits of the two main
aperistaltic agents, HBB (Buscopan®) and glucagon. To
date no prospective study has compared these two agents
regarding their impact on small bowel motion in cross-
sectional imaging. Our study shows a clear advantage for
glucagon with a significantly greater efficiency and a
significantly longer effect of paralysis.
Various other authors [10–12] have already qualita-
tively compared the spasmolytic, duodenal distension and
coating effects of glucagon and HBB in double-contrast
barium meal examinations. Prolonged gastric visualiza-
tion was reported with 0.5 mg i.v. glucagon compared
with 20 mg HBB. Opposing effects of glucagon (hyper-
tonic) and HBB (hypotonic) on gastric emptying and
duodenal filling influenced by the tonicity of the pyloric
sphincter explain the specific findings in these previous
studies limiting their extrapolation to cross-sectional
imaging techniques.
Despite their completely different action site and
pharmacology [4, 5], HBB and glucagon have an early
and rapid onset that occurs more or less in parallel with the
arterial first-pass effect in the abdomen. The effects of both
drugs start approximately 30 s after injection with no
measurable location-dependent difference regarding mo-
tility. Apparently, the muscarinic receptors and glucagon
receptors are expressed in similar compartments.
Glucagon was clearly more effective at inducing spasmol-
ysis than HBB: all glucagon volunteers achieved complete
arrest of bowel motion versus only 50% of HBB volunteers.
Our results also show that glucagon induces a significantly
longer duration of paralytic effect than HBB. The period of
complete arrest of bowel motion needed for imaging is about
threefold longer after 1 mg glucagon than after 40 mg HBB.
This exemplifies the lower absolute plasma glucagon
concentration needed to arrest bowel wall motion compared
with HBB [4]. Potentially, lower doses of glucagon may be
sufficient to induce shorter periods of aperistalsis, but this
was not investigated in the present study.
Despite the rather small scale of this study from an
imaging perspective, its findings clearly have practical
consequences. Glucagon has several advantages over HBB
for complete elimination of bowel wall motion in abdom-
inal imaging. Glucagon has a fast and more reliable onset
and allows prolonged MRI studies with no intestinal
movement for about 18 min. This however awaits further
confirmation in large-scale clinical trials.
We undertook this prospective volunteer study also to
evaluate the MRI method as a robust tool for evaluation of
bowel motility.
In a previous feasibility study we were able to
demonstrate that MRI might be useful for assessment of
small bowel peristalsis [6]; however, in the feasibility study
the sequence duration was only 30 s, whereas the
sequences used in the present trial allowed monitoring
over a period of 60 min.
The technical results of the present trial demonstrate that
MRI is a valuable, robust and reproducible tool for
evaluating small bowel peristalsis in healthy volunteers
even over a time period of 1 h.
To our knowledge, this is the first prospective study that
directly compares the two main spasmolytic drugs on the
visualisation of small bowel wall motion. This parameter is
deemed the most important factor for successful imaging,
since bowel-motion-related artefacts are the main problems
to be overcome by premedication for reliable cross-
sectional imaging of the abdomen and pelvis.
The clear gold standard for assessment of small bowel
motility is still manometry via a pressure-sensitive tube
placed in the small bowel [13, 14]. It should be
emphasised, though, that this technique records only
contractions where the lumen fully closes. This measure-
ment is fundamentally different from visualisation of bowel
wall motion by MRI. Another way to monitor small bowel
motion is by analysing the electrophysiological properties
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that propel the contraction over the small bowel wall
(impedancometry). This technique is comparable to elec-
trocardiogram for measuring heart physiology(ECG) [15].
It cannot be done, however, by simple placement of
electrodes on the body surface, rather they must be applied
directly to the surface of the bowel wall which renders the
method useless in a clinical setting.
Measuring small bowel motion by MRI has several
advantages over the two techniques just mentioned. First, it
allows depiction of the entire length of the small bowel,
which neither of the other methods does. Second, it is
completely noninvasive. Third, it is easy-to-apply and
reproducible, whereas both other techniques are inconve-
nient for patients and little used in clinical practice [6, 16]
There are several limitations to our study. Correlation to
a standard method is lacking and should be evaluated in a
future trial. In the present study we wanted first to prove its
feasibility for time periods of up to 1 h, which can yield a
huge amount of data. In this study we collected more than
70,000 measurements by hand and transferred them into a
database. The evaluation itself consisted of another 1,000
data points. Certainly, acquiring this amount of data by
hand will pose a problem in future studies. There is a clear
need for computational support and semiautomated
techniques that can simplify the data acquisition of small
bowel motion assessment for further studies.
The aperistaltic characteristics of both drugs cannot be
extrapolated to other administration routes, such as subcu-
taneous injection [4, 8, 17]. Future studies must compare
the relative merits of the various administration routes.
In conclusion, glucagon appears to be superior to
HBB for small bowel paralysis in cross-sectional
imaging of the abdomen and pelvis. Glucagon is
significantly more reliable for the onset of effect and
induces complete arrest of bowel motion lasting
roughly three times longer than with HBB. It remains
for future studies to correlate the findings of our study
with a standard method, such as manometry.
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